MES cells exhibit in vitro, more resistant to chemotherapeutics, retinoic acid, and ALK inhibition [21, 22, 58, 59], drugs that are applied in current first- and second-line treatment protocols for patients with neuroblastoma [21, 22, 58, 59]. This evidence concerns the gene ALK and neuroblastoma.